Elevated glycogen synthase kinase-3 activity in Fragile X mice: Key metabolic regulator with evidence for treatment potential

Wenzhong William Min, Christopher J. Yuskaitis, Qijiang Yan, Christopher Sikorski, Shengqiang Chen, Richard S Jope, Robert P. Bauchwitz

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Significant advances have been made in understanding the underlying defects of and developing potential treatments for Fragile X syndrome (FXS), the most common heritable mental retardation. It has been shown that neuronal metabotropic glutamate receptor 5 (mGluR5)-mediated signaling is affected in FX animal models, with consequent alterations in activity-dependent protein translation and synaptic spine functionality. We demonstrate here that a central metabolic regulatory enzyme, glycogen synthase kinase-3 (GSK3) is present in a form indicating elevated activity in several regions of the FX mouse brain. Furthermore, we show that selective GSK3 inhibitors, as well as lithium, are able to revert mutant phenotypes of the FX mouse. Lithium, in particular, remained effective with chronic administration, although its effects were reversible even when given from birth. The combination of an mGluR5 antagonist and GSK3 inhibitors was not additive. Instead, it was discovered that mGluR5 signaling and GSK3 activation in the FX mouse are coordinately elevated, with inhibition of mGluR5 leading to inhibition of GSK3. These findings raise the possibility that GSK3 is a fundamental and central component of FXS pathology, with a substantial treatment potential.

Original languageEnglish
Pages (from-to)463-472
Number of pages10
JournalNeuropharmacology
Volume56
DOIs
StatePublished - Feb 1 2009
Externally publishedYes

Fingerprint

Glycogen Synthase Kinase 3
Metabotropic Glutamate 5 Receptor
Fragile X Syndrome
Lithium
Excitatory Amino Acid Antagonists
Metabotropic Glutamate Receptors
Protein Biosynthesis
Intellectual Disability
Spine
Animal Models
Parturition
Pathology
Phenotype
Brain
Enzymes

Keywords

  • Audiogenic seizures
  • Behavior
  • Fragile X
  • GSK3
  • Lithium
  • mGluR

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Elevated glycogen synthase kinase-3 activity in Fragile X mice : Key metabolic regulator with evidence for treatment potential. / Min, Wenzhong William; Yuskaitis, Christopher J.; Yan, Qijiang; Sikorski, Christopher; Chen, Shengqiang; Jope, Richard S; Bauchwitz, Robert P.

In: Neuropharmacology, Vol. 56, 01.02.2009, p. 463-472.

Research output: Contribution to journalArticle

Min, Wenzhong William ; Yuskaitis, Christopher J. ; Yan, Qijiang ; Sikorski, Christopher ; Chen, Shengqiang ; Jope, Richard S ; Bauchwitz, Robert P. / Elevated glycogen synthase kinase-3 activity in Fragile X mice : Key metabolic regulator with evidence for treatment potential. In: Neuropharmacology. 2009 ; Vol. 56. pp. 463-472.
@article{50b182c553404ed8ab854b543c125883,
title = "Elevated glycogen synthase kinase-3 activity in Fragile X mice: Key metabolic regulator with evidence for treatment potential",
abstract = "Significant advances have been made in understanding the underlying defects of and developing potential treatments for Fragile X syndrome (FXS), the most common heritable mental retardation. It has been shown that neuronal metabotropic glutamate receptor 5 (mGluR5)-mediated signaling is affected in FX animal models, with consequent alterations in activity-dependent protein translation and synaptic spine functionality. We demonstrate here that a central metabolic regulatory enzyme, glycogen synthase kinase-3 (GSK3) is present in a form indicating elevated activity in several regions of the FX mouse brain. Furthermore, we show that selective GSK3 inhibitors, as well as lithium, are able to revert mutant phenotypes of the FX mouse. Lithium, in particular, remained effective with chronic administration, although its effects were reversible even when given from birth. The combination of an mGluR5 antagonist and GSK3 inhibitors was not additive. Instead, it was discovered that mGluR5 signaling and GSK3 activation in the FX mouse are coordinately elevated, with inhibition of mGluR5 leading to inhibition of GSK3. These findings raise the possibility that GSK3 is a fundamental and central component of FXS pathology, with a substantial treatment potential.",
keywords = "Audiogenic seizures, Behavior, Fragile X, GSK3, Lithium, mGluR",
author = "Min, {Wenzhong William} and Yuskaitis, {Christopher J.} and Qijiang Yan and Christopher Sikorski and Shengqiang Chen and Jope, {Richard S} and Bauchwitz, {Robert P.}",
year = "2009",
month = "2",
day = "1",
doi = "10.1016/j.neuropharm.2008.09.017",
language = "English",
volume = "56",
pages = "463--472",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Elevated glycogen synthase kinase-3 activity in Fragile X mice

T2 - Key metabolic regulator with evidence for treatment potential

AU - Min, Wenzhong William

AU - Yuskaitis, Christopher J.

AU - Yan, Qijiang

AU - Sikorski, Christopher

AU - Chen, Shengqiang

AU - Jope, Richard S

AU - Bauchwitz, Robert P.

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Significant advances have been made in understanding the underlying defects of and developing potential treatments for Fragile X syndrome (FXS), the most common heritable mental retardation. It has been shown that neuronal metabotropic glutamate receptor 5 (mGluR5)-mediated signaling is affected in FX animal models, with consequent alterations in activity-dependent protein translation and synaptic spine functionality. We demonstrate here that a central metabolic regulatory enzyme, glycogen synthase kinase-3 (GSK3) is present in a form indicating elevated activity in several regions of the FX mouse brain. Furthermore, we show that selective GSK3 inhibitors, as well as lithium, are able to revert mutant phenotypes of the FX mouse. Lithium, in particular, remained effective with chronic administration, although its effects were reversible even when given from birth. The combination of an mGluR5 antagonist and GSK3 inhibitors was not additive. Instead, it was discovered that mGluR5 signaling and GSK3 activation in the FX mouse are coordinately elevated, with inhibition of mGluR5 leading to inhibition of GSK3. These findings raise the possibility that GSK3 is a fundamental and central component of FXS pathology, with a substantial treatment potential.

AB - Significant advances have been made in understanding the underlying defects of and developing potential treatments for Fragile X syndrome (FXS), the most common heritable mental retardation. It has been shown that neuronal metabotropic glutamate receptor 5 (mGluR5)-mediated signaling is affected in FX animal models, with consequent alterations in activity-dependent protein translation and synaptic spine functionality. We demonstrate here that a central metabolic regulatory enzyme, glycogen synthase kinase-3 (GSK3) is present in a form indicating elevated activity in several regions of the FX mouse brain. Furthermore, we show that selective GSK3 inhibitors, as well as lithium, are able to revert mutant phenotypes of the FX mouse. Lithium, in particular, remained effective with chronic administration, although its effects were reversible even when given from birth. The combination of an mGluR5 antagonist and GSK3 inhibitors was not additive. Instead, it was discovered that mGluR5 signaling and GSK3 activation in the FX mouse are coordinately elevated, with inhibition of mGluR5 leading to inhibition of GSK3. These findings raise the possibility that GSK3 is a fundamental and central component of FXS pathology, with a substantial treatment potential.

KW - Audiogenic seizures

KW - Behavior

KW - Fragile X

KW - GSK3

KW - Lithium

KW - mGluR

UR - http://www.scopus.com/inward/record.url?scp=58849126410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849126410&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2008.09.017

DO - 10.1016/j.neuropharm.2008.09.017

M3 - Article

C2 - 18952114

AN - SCOPUS:58849126410

VL - 56

SP - 463

EP - 472

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -